Equillium wins Australian regulatory clearance for EQ504 Phase 1 trial
EQ•Equillium received Australian regulatory clearance to begin a first-in-human Phase 1 trial of EQ504, with first dosing expected by early November 2026 and topline data projected about six months later.
1. Trial timeline
Equillium secured Australian Therapeutic Goods Administration clearance under the CTN scheme and received HREC approval for its EQ504 Phase 1 trial. First dosing is expected by early November 2026, with topline data projected about six months later. The program supports a potential ulcerative colitis proof-of-concept study in the second half of 2027, pending Phase 1 results.
